Exclusive Sponsor - Law Firm
Cooley
Cooley is a full-service global law firm, having more than 1300 lawyers across 19 offices in Asia, Europe and the United States. For over 40 years, Cooley has played an instrumental role in the growth of many of the most disruptive and sophisticated companies in the life sciences and healthcare industry. We deliver an unparalleled combination of innovative legal expertise, deep industry knowledge and practical understanding of our clients' business needs.
We actively represent 2,500+ public and private life sciences and healthcare companies worldwide and advise them and their investors on a variety of strategic transactions cross their life cycle, such as private financing, corporate partnering and licensing, complex mergers and acquisitions, joint venture, capital markets, intellectual property issues, regulatory counselling, supply and distribution arrangements and other commercial transactions.
https://www.cooley.com/services/industry/life-sciences
Exclusive Sponsor - Accounting Firm
PwC
With offices in 151 countries and more than 364,000 people, we are among the leading professional services networks in the world. We help organizations and individuals create the value they are looking for, by delivering quality in Assurance, Tax, and Advisory services.
At PwC, our purpose is to build trust in society and solve important problems. In an increasingly complex world, we help intricate systems function, adapt and evolve so they can deliver sustained outcomes for communities and society – whether they are capital markets, tax systems or the economic systems within which business and society exist.
We are proud that more than 178,000 organizations – including 87% of the Fortune Global 500 – choose to work with us to provide globally industry-focused assurance, consulting & deals and tax services for them. Our smaller-scale listed, private and government clients also benefit from the same depth of cross-industry expertise and professional services.
Gold Sponsor
BioTrack
Established in 2017, BioTrack is a venture capital firm that focuses on investing in and incubating outstanding early-stage biotech, medtech as well as healthcare cross disciplinary sectors (AI and digital healthcare, consumer healthcare, etc). Our professional investment team possess strong and complementary skills in research and development, clinical operations, consulting, and investment.
BioTrack positions itself both as an investor and a long-term partner for entrepreneurs. To date, BioTrack has invested more than 100 portfolio companies, with many of them have grown to become public companies and sub-sector leaders such as OBiO (688238.SH), Asieris (688176.SH), TYK Medicines (2410.HK), Innogen(2591.HK), CF PharmTech(2652.HK), LaNova, BioNova, OnCusp, and Ligatech, etc. Besides that, the team in their career invested in numerous industry leaders such as BGI Genomics (300676.SZ), Betta Pharmaceuticals (300558.SZ), Zai Lab (ZLAB.NASDAQ), Yuwell (002223.SZ), Baheal Medical (301015.SZ), Bright Eye Hospital (301239.SH), Medtrum, WEGO (01066.HK), and Sunhere Pharma (300452.SZ), etc.
The firm currently manages five funds, with total assets under management over USD1.5Bn，continuously recognized by top-tier LPs worldwide, including pension funds, endowments, foundations, FOF, family offices, and strategic partners, etc.
Since its inception, BioTrack distinguishes itself as the entrepreneur founded VC with extensive industry ecosystem. Its ecosystem consists of leading global biopharma, medtech companies and other multinational healthcare conglomerates, which not only provide deep industry insights and value-add service but also empower its portfolio companies in going overseas and global expansion.
Silver Sponsor
OrbiMed
Established in 1989, OrbiMed is healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$14 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 400 private companies across a wide range of therapeutic categories and stages of development. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 40 companies.
Lunch Sponsor
C-Ray Therapeutics
C-Ray Therapeutics is a leading global CRDMO dedicated to end-to-end radiopharmaceutical solutions. With 28,000 sqm of integrated R&D and cGMP manufacturing facilities, we support over 30 radioisotopes at commercial scale. We have managed over 60 projects, from preclinical to Phase III trials, and excel in securing critical isotopes like Ac-225, having supported 16 related programs. Backed by over USD 187 million in funding, we provide reliable development and manufacturing services worldwide.